All Updates

All Updates

icon
Filter
Funding
Phenomix Sciences raises USD 5.5 million in Series A funding and USD 2.3 million in grant funding to accelerate commercialization and adoption of MyPhenome test
Precision Medicine
May 16, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Regulation/policy
Product updates
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
Precision Medicine

Precision Medicine

May 16, 2024

Phenomix Sciences raises USD 5.5 million in Series A funding and USD 2.3 million in grant funding to accelerate commercialization and adoption of MyPhenome test

Funding

  • Phenomix Sciences has raised USD 5.5 million in a Series A funding round, with participation from existing investor Health2047 and new investors DexCom Inc. and Labcorp. Additionally, the company received a USD 2.3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

  • The raised funds are expected to accelerate the commercialization of the MyPhenome test in the sector of obesity specialists and the broader industry. The test is claimed to identify obesity phenotypes and provide physicians with tools to create effective treatment plans, including lifestyle and diet interventions, as well as medication and procedure recommendations.

  • Phenomix Sciences is a biotechnology company focused on precision medicine for obesity treatment. It leverages genetic testing and data analytics to categorize obesity into phenotypes, which enables personalized treatment plans to optimize outcomes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.